Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.surg.2024.109112 | DOI Listing |
Surgery
January 2025
Department of Information Technology, General Hospital of Xinjiang Military Command of PLA, Urumqi, PR China. Electronic address:
Toxicol Res (Camb)
February 2025
Toxicology Centre, University of Saskatchewan, 44 Campus Drive, Saskatoon, SK S7N 5B3, Canada.
The mining industry, including uranium mining and milling, is of high importance in Canada. It is, however, important to consider that ore processing can result in the creation of by-products that contain radionuclides such as radium-226 (Ra). Even with the strict discharge regulations in place, there is limited evidence to suggest that the current Canadian regulatory thresholds for Ra are protective for aquatic life.
View Article and Find Full Text PDFActa Diabetol
January 2025
Endocrinology Department, Unidade Local de Saúde Tâmega e Sousa, Penafiel, Portugal.
Introduction: Women with first trimester fasting glycaemia (FTFG) 92-125 mg/dL may present with normal 24-28th week OGTT (2T-OGTT). Predictors of persistent hyperglycaemia were scarcely investigated. We studied the prevalence and predictors of gestational diabetes mellitus (GDM) in the 2T-OGTT in women with untreated elevated FTFG.
View Article and Find Full Text PDFThe conclusions of the European Food Safety Authority (EFSA) following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State Austria for the pesticide active substance lysate of C2c Maky and the considerations as regards the inclusion of the substance in Annex IV of Regulation (EC) No 396/2005 are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative use of lysate of C2c Maky as a fungicide against downy mildew () on grapevines and table grapes.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
January 2025
Department of Neurology, Weill Cornell Medicine, New York NY, USA.
Accumulating evidence suggests that the effects of menopausal hormone therapy (MHT) on risk of Alzheimer's disease (AD) and all-cause dementia are influenced by timing of initiation relative to age and time-since-menopause and the type of formulation. Randomized clinical trials (RCTs) of MHT conducted in older postmenopausal women indicate an increased risk of dementia. While RCTs conducted in midlife are lacking, observational research has provided evidence for associations between midlife estrogen-only therapy (ET) use and a reduced risk of AD dementia, whereas estrogen-progestogen therapy (EPT) is associated with more variable outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!